

On behalf of Genentech, you are invited to attend  
an expert-led educational presentation

## Introducing TECENTRIQ<sup>™</sup>: The First and Only FDA-Approved Anti-PDL1 Immunotherapy for Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

**Thursday, September 29, 2016**  
**Presentation Time: 1:00 PM Eastern**  
**Time, 12:00 PM Central Time, 11:00 AM**  
**Mountain Time, 10:00 AM Pacific Time**

### Genentech Webcast

#### FEATURED FACULTY

John Powderly, MD  
Carolina BioOncology Institute, PLLC  
Huntersville, NC

**Please RSVP by visiting**  
**<http://www.medforcereg.net/SGEN6125>**

#### PROGRAM OBJECTIVES:

- Introduction to urothelial carcinoma
- Review Important Safety Information
  - Review of the warnings and precautions and other Important Safety Information
- Present the pivotal clinical data
- Identify appropriate patient candidates for TECENTRIQ
- Provide PI recommendations for managing immune-related adverse events

#### INDICATIONS AND USAGE

TECENTRIQ (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Minnesota, Vermont, the Department of Defense, and the Department of Veterans Affairs have restrictions on receiving meals at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict your participation in this event. Your local Genentech representative can help you determine if our policies permit your attendance. When you RSVP, please indicate whether you will accept or opt out of accepting a meal at the program. If you choose to opt out, you may either pay for the meal on your own or not consume anything at the program.

For all attendees who opt in to accept a meal paid for by Genentech at this event, Genentech will report the attendee's name and the value of the meal, as required by federal and state disclosure laws (for more information on the federal law please visit <http://sunshine.gene.com>). The meal cost may vary by event location and be up to \$125 per person (exceptions may apply).

**Please see accompanying full Prescribing Information and reverse for Important Safety Information.**

**Genentech**  
A Member of the Roche Group

## Important Safety Information for TECENTRIQ™ (atezolizumab)

### Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-related pneumonitis**, including fatal cases. Permanently discontinue TECENTRIQ for grade 3 or 4 pneumonitis
- **Immune-related hepatitis**. Immune-mediated hepatitis, including a fatal case, and liver test abnormalities have occurred. Permanently discontinue TECENTRIQ for grade 3 or 4 immune-mediated hepatitis
- **Immune-related colitis**, including a fatal case of diarrhea-associated renal failure. Permanently discontinue TECENTRIQ for grade 4 diarrhea or colitis
- **Immune-related endocrinopathies**. Immune-related thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have occurred. Permanently discontinue TECENTRIQ for grade 4 hypophysitis. For specific information on dose modifications, refer to Prescribing Information
- **Other immune-related adverse reactions**. Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, ocular inflammatory toxicity, and pancreatitis, including increases in serum amylase and lipase levels, have occurred. Permanently discontinue TECENTRIQ for any grade of meningitis or encephalitis; or myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Permanently discontinue TECENTRIQ for grade 4 or any grade of recurrent pancreatitis
- **Infection**, including fatal cases. Severe infections, including sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage have occurred
- **Infusion-related reactions** have occurred. Permanently discontinue TECENTRIQ in patients with grade 3 or 4 infusion reactions
- **Embryo-fetal toxicity**. TECENTRIQ can cause fetal harm in pregnant women. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

### Most Common Adverse Reactions

The most common adverse reactions (rate  $\geq 20\%$ ) included fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation.

You may report side effects to the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at 1-888-835-2555.

**Please see accompanying full Prescribing Information for additional Important Safety Information.**

**Genentech**

*A Member of the Roche Group*

© 2016 Genentech USA, Inc. All rights reserved. PDL/121615/0163 Printed in USA

 **TECENTRIQ™**  
atezolizumab INJECTION USP  
800mg/100mL (3.6mL)